Huai L. Pisaniello

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Intra-articular hyaluronic acid for osteoarthritis.

Intra-articular hyaluronic acid for osteoarthritis.

Journal: Australian prescriber
Published: June 18, 2026

Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis: is it effective?

Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis: is it effective?

Journal: Australian prescriber
Published: February 25, 2026

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.

Journal: The Cochrane database of systematic reviews
Published: September 30, 2025

The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).

The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).

Journal: Annals of the rheumatic diseases
Published: February 19, 2024

Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).

Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).

Journal: RMD open
Published: December 23, 2022

Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis.

Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis.

Journal: BMC rheumatology
Published: March 01, 2022

Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.

Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.

Journal: Internal medicine journal
Published: February 25, 2022

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Journal: Nature reviews. Rheumatology
Published: June 28, 2021

Heterogeneity in the association between weather and pain severity among patients with chronic pain: a Bayesian multilevel regression analysis.

Heterogeneity in the association between weather and pain severity among patients with chronic pain: a Bayesian multilevel regression analysis.

Journal: Pain reports
Published: June 10, 2021

Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.

Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.

Journal: Seminars in arthritis and rheumatism
Published: April 05, 2021

Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.

Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.

Journal: Arthritis research & therapy
Published: October 18, 2020

Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.

Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.

Journal: Rheumatology advances in practice
Published: July 10, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026